Pennsylvania-baserte JBS Science sa i dag at de mottok 3 millioner dollar Bridge Award for Small Business Innovation Research IIB fra National Cancer Institute. Selskapet utviklet det første flytende biopsiproduktet, som er urin-DNA-screening for tidlig levercellekreft (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of leverkreft. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating svulst DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS sa at de har samarbeidet med James Hamilton fra Johns Hopkins University Medical Center og Hie-Won Hann fra Thomas University Hospital for å fremme utviklingen av leverkreft urinprøve.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
